___

• [1] “Epidemiology, clinical manifestations, and diagnosis of herpes zoster - UpToDate”. . [2] P. K. Wung vd., “Herpes zoster in immunocompromised patients: Incidence, timing, and risk factors”, Am. J. Med., c. 118, sayı 12, ss. 1416.e9-1416.e18, Ara. 2005, doi: 10.1016/J.AMJMED.2005.06.012. [3] G. AJ, R. DA, S. KN, ve F. DW, “Frequency, cost, and risk factors of readmissions among severe sepsis survivors”, Crit. Care Med., c. 43, sayı 4, ss. 738–746, Nis. 2015, doi: 10.1097/CCM.0000000000000859. [4] T. R. C. Group, “Dexamethasone in Hospitalized Patients with Covid-19”, https://doi.org/10.1056/NEJMoa2021436, c. 384, sayı 8, ss. 693–704, Tem. 2020, doi: 10.1056/NEJMOA2021436. [5] L. TJ, “Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity”, Ophthalmology, c. 115, sayı 2 Suppl, Şub. 2008, doi: 10.1016/J.OPHTHA.2007.10.009. [6] T. M. Chen, S. George, C. A. Woodruff, ve S. Hsu, “Clinical manifestations of varicella-zoster virus infection”, Dermatol. Clin., c. 20, sayı 2, ss. 267–282, 2002, doi: 10.1016/S0733-8635(01)00012-2. [7] M. Sachdeva vd., “Cutaneous manifestations of COVID-19: Report of three cases and a review of literature”, J. Dermatol. Sci., c. 98, sayı 2, ss. 75–81, May. 2020, doi: 10.1016/J.JDERMSCI.2020.04.011. [8] A. C. A. de F. Ferreira, T. T. Romão, Y. S. Macedo, C. Pupe, ve O. J. M. Nascimento, “COVID-19 and herpes zoster co-infection presenting with trigeminal neuropathy”, Eur. J. Neurol., c. 27, sayı 9, ss. 1748–1750, Eyl. 2020, doi: 10.1111/ENE.14361.